Royalty Report: Drugs, Disease, Diabetes Treatment – Collection: 275798

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Disease
  • Diabetes Treatment
  • Therapeutic
  • obesity
  • Delivery
  • Device
  • Drug Discovery
  • implants
  • Biotechnology
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 275798

License Grant
The Parties previously entered into a related Feasibility Study Agreement.  This agreement is for the development, manufacture and commercialization of an injectable long-acting formulation of AC2993 (synthetic exendin–4).

Licensor grants an exclusive, worldwide license in the Field under Licensor Patents and Licensor Know-How, together with the right to grant sublicenses, to make, have made, use, import, offer to sell, sell and have sold Products.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
The intellectual property rights are relating to injectable, sustained release formulation systems, including the Medisorb(R) microsphere system, a patented and proprietary (Medisorb(R)) injectable sustained release drug delivery technology.

AC2993 means synthetic exendin-4.

Product means any Field Product the manufacture, use, sale, offer for sale, or import of which, but for the licenses granted in this Agreement, would infringe a Valid Claim of any of the Licensor Patents.

The patents include Preparation of Biodegradable Microparticles Containing a Biologically Active Agent, Preparation of Extended Shelf-Life Biodegradable, Biocompatible Microparticles Containing a Biologically Active Agent,  Method for Preparing Microparticles Having a Selected Release Profile, Apparatus and Method for Preparing Microparticles Using an In-line Solvent Extraction;  and, Apparatus and Method for Preparing Micropartides.

Field of Use
Field means System formulations of Field Products.  

Field Products mean Exendins (including AC2993), exendin agonists, GLP-1 and GLP-1 agonists. The initial Field Product will be AC2993.

AC2993 is a diabetes drug candidate.

IPSCIO Record ID: 203477

License Grant
Pursuant to this agreement, the Parties agree to collaborate on an exclusive basis in the Development and Commercialization of Product in the Field.

Licensor grants an exclusive license in the Territory except for the U.S. with the right to sublicense, under the Licensor Rights existing as of the Effective Date, solely to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Field in the Territory except for the U.S. as contemplated by this Agreement, and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Licensor grants a non-exclusive, worldwide license, including the right to sublicense, to use the Licensor Marks on Product packaging, labeling, advertising and Promotional Material.

For IT improvements, Licensor grants a worldwide, nonexclusive license in the Territory to practice under the rights of Licensor to any such Licensor Rights and Improvements to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Territory as contemplated by this Agreement, and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Each Party hereby grants the other Party an exclusive option to enter into an agreement for the Development of Option Compound(s) Controlled by the granting Party.

License Property
The Neogenesis patents are claiming differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4.

The Compound means exendin-4, an amino acid sequence.

AC2993 (synthetic exendin-4) is a peptide that has been shown to stimulate insulin secretion when blood glucose concentrations are high, but not when blood glucose levels are low.

The Product means a pharmaceutical product that contains or incorporates Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration (including, without limitation, all delivery devices or other peripherals and consumables).

U.S. 5,424,286

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.

This collaboration agreement is for development and sale of a potential new treatment for type 2 diabetes.

IPSCIO Record ID: 215177

License Grant
Pursuant to this agreement, the Parties agree to collaborate on an exclusive basis in the Development and Commercialization of Product in the Field.

Licensor grants an exclusive license in the Territory, with the right to sublicense, under the Licensor Rights existing as of the Effective Date, solely to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Field in the Territory as contemplated by this Agreement and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Licensor grants a non-exclusive, worldwide license, including the right to sublicense in conjunction with a sublicense permitted by this agreement, to use the Licensors Marks on Product packaging, labeling, advertising and Promotional Material.

For IT improvements, Licensor grants a worldwide, nonexclusive license in the Territory to practice under the rights of Licensor to any such Licensor Rights and Improvements to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Territory as contemplated by this Agreement and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Each Party grants the other Party an exclusive option to enter into an agreement for the Development of Option Compound(s) Controlled by the granting Party.

License Property
The Neogenesis patents are claiming differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4.

The Compound means exendin-4, an amino acid sequence.

AC2993 (synthetic exendin-4) is a peptide that has been shown to stimulate insulin secretion when blood glucose concentrations are high, but not when blood glucose levels are low.

The Product means a pharmaceutical product that contains or incorporates Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration (including, without limitation, all delivery devices or other peripherals and consumables).

U.S. 5,424,286

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.

This collaboration agreement is for development and sale of a potential new treatment for type 2 diabetes.

IPSCIO Record ID: 294293

License Grant
Licensor grants an exclusive, worldwide license under the Licensor IP Rights, Licensor Research IP Rights, and Licensors rights under the Joint Research IP Rights to develop, make, have made, use, offer for sale, sell, have sold, export and import the Product for use in the Field.
License Property
The Product shall mean a biodegradable, preformed, macroscopic implant device consisting of the Active Agent, as the sole active pharmaceutical ingredient, incorporated into the Delivery Matrix.

The joint research is for Implants for the treatment of dopamine associated states, meaning Biodegradable implant containing a dopamine modluating compound.

Licensor patents include Methods for manufacturing delivery systems and systems, and, Modulating burst and release profiles from coestruded implants by treating implant ends, and, Influencing drug release  profiles from implants by selectively adjusting the location and amount of drug loading, and, Implant devices that differ by release profile and methods of making and using same.

Field of Use
Parties have been collaborating since on the development of a biodegradable sustained release formulation of an approved dopamine agonist. The result is Licensee’s NP201, the first long-acting treatment available in broadly acceptable dose form that maintains the potential to provide sustained relief from Parkinson’s disease without motor response complications. NP201 leverages Licensee’s long-acting delivery (LAD™) technology and Licensee’s proprietary biodegradable polymer matrix implant technology to achieve optimal drug release over an extended period of time.

IPSCIO Record ID: 4389

License Grant
The Company acquired a license agreement which allows the Company to use controlled delivery technology that may prove useful in the delivery of basal insulin.
License Property
AB101 is a PEGylated basal insulin that has been formulated in biodegradable microspheres to be injected weekly to treat patients with Type 1 and Type 2 diabetes who require basal insulin to control hyperglycemia.
Field of Use
An early-stage development company focused on developing and commercializing proprietary technology to be used with active pharmaceutical ingredients to create sustained release injectable formulations has a license relative to their lead product candidate AB101, which is a potential once-a-week basal insulin injection for the diabetes market.  AB101 for the diabetes market and other product candidates uses the proprietary sustained release formulation capability. As a precursor to clinical studies, they will study the pharmacokinetics and pharmacodynamics of AB101 in two animal species.

IPSCIO Record ID: 275800

License Grant
Licensor grants to Licensee of Barbados an exclusive license in the Territory under the Patent Rights, Know-How and Technical Information, with the right, to grant sublicenses of the same scope as the license granted by this Agreement, or to appoint a Distributor, to Manufacture and Market 500mg Product in, and import 500mg Product into, the Territory.

Licensor grants to Licensee of Barbados a non-exclusive license under the Foreign Patent Rights, Know-How and Technical Information, with the right, to grant sublicenses of the same scope as the license granted, to Manufacture 500mg Product in the United States or Puerto Rico for export to the Territory for sale in the Territory in compliance with this Agreement.

License Property
The Active Ingredient shall mean the chemical compound known as metformin HCl.

The 500mg Product shall mean the once-daily oral formulation of the Active Ingredient in combination with the AcuForm Delivery Technology.

The 1000mg Product shall mean the once daily oral tablet formulation of the Active Ingredient in a 1000 mg strength to be developed using proprietary Licensee drug delivery technology pursuant to the Supply Agreement.

Invention shall mean the 500mg Product, any improvement to the 500mg Product, any new use of the 500mg Product, any new performance characteristic of the 500mg Product, any new process used to Manufacture the 500mg Product, or any step or steps in any such process, and includes all formulations of the 500mg Product developed pursuant to the Prior Agreement.

The patents are titles:  Extending the Duration of Drug Release Within the Stomach During the Fed Mode; Gastric-Retentive, Oral Drug Dosage Forms for the Controlled Release of Sparingly Soluble Drugs and Insoluble Matter;  Alkyl-Substituted Cellulose-Based Sustained Release Oral Drug Dosage Forms;  and, Sustained-release oral drug dosage form.

Field of Use
The field of use for the metformin product is Type II diabetes.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.